Aflibercept for untreated diabetic macular oedema TS ID 10621Status:Topic selectionProgramme:Technology appraisal guidanceExpected publication date: TBC
Cardiometabolic disease prevention and treatment guidelinesStatus:In developmentProgramme:NICE HubExpected publication date: TBC
Endoscopic duodenal mucosal resurfacing for type 2 diabetesStatus:In developmentProgramme:Interventional procedures guidanceExpected publication date: 16 May 2024
Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema (TA953)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 13 March 2024
Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes (TA943)Product type:GuidanceProgramme:Technology appraisal guidancePublished: 19 December 2023
Teplizumab for delaying the onset of type 1 diabetes in people 8 years and over at risk of developing the condition [ID6259]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Type 2 diabetes in adults: management (medicines update)Status:In developmentProgramme:NICE guidelineExpected publication date: 4 December 2024